This trial looks at the effectiveness and safety of a medicine called olverembatinib when combined with chemotherapy. It is for patients with newly diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal is to see if this combination works better than other treatments chosen by doctors.
This is a Phase 3 study, which means it's looking at how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include about 350 participants.
Who can join
Anyone 18 years or older with newly diagnosed Ph+ ALL can join. Participants must be expected to live at least 3 months and have good organ function. Some people cannot join, like those with certain previous health issues or active infections. The trial team will check who is eligible.
Conditions
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups by chance. One group will receive olverembatinib with chemotherapy. The other group will get a different treatment chosen by their doctor, also with chemotherapy. Everyone will take their assigned treatment as directed, either daily or every other day.
Where
This trial is enrolling at 16 locations. Recruiting sites are listed first.
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.